Your browser doesn't support javascript.
loading
Case Report: Paliperidone Palmitate in the Management of Bipolar I Disorder With Non-compliance.
Li, Kanglai; Liao, Yingtao; Yang, Zhihua; Yang, Caishuang; Chen, Minhua; Wu, Xiuhua; Gan, Zhaoyu.
Afiliación
  • Li K; Very Important Patients Department, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Liao Y; Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Yang Z; Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Yang C; Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Chen M; Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Wu X; Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • Gan Z; Department of Psychiatry, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Front Psychiatry ; 11: 529672, 2020.
Article en En | MEDLINE | ID: mdl-33488408
Background: Medication non-adherence is prevalent in patients with bipolar disorder (BD). Long-acting injectable antipsychotics (LAIAs) are widely used to improve compliance with treatment. This study aimed to illustrate the effectiveness, compliance, and safety profile of once-monthly paliperidone palmitate (PP1M), a novel therapeutic LAIA, in the management of bipolar I disorder (BDI). Method: A prospective follow-up was arranged to 11 BDI patients who were prescribed PP1M as monotherapy or adjunctive treatment. Severity of symptoms, disturbing behavior, status of employment, 17-item Hamilton Depression Rating Scale (HAMD-17), and Young Mania Rating Scale (YMRS) were evaluated at the baseline and the endpoint of follow-up. Clinical Global Impression-Bipolar Disorder-Severity of Illness Scale (CGI-BP) and Treatment Emergent Symptom Scale (TESS) were measured at each injection of PP1M. Compliance, relapse or switch, and new hospitalization were monitored through the period of follow-up. Results: The median duration of treatment was 14 months, ranging from 5 to 22 months. The scores (mean ± standard deviation) of HAMD-17, YMRS, and CGI-BP generally decreased from the baseline (16.1 ± 10.3, 30.9 ± 12.6, 5.3 ± 0.7) to the endpoint (7.4 ± 5.7, 3.7 ± 3.2, 2.3 ± 0.7). No disturbing behavior was detected at the endpoint. Neither new hospitalization nor manic/mixed episode occurred during treatment, whereas mild to moderate depressive episodes were reported in three cases. The status of employment of 10 participants (90.9%) was improved, and no new safety concern was detected. Conclusion: PP1M might offer a new valid treatment option in the long-term management of BDI, especially for those with poor compliance with oral medication. However, more studies are needed to further justify such role.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Psychiatry Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Front Psychiatry Año: 2020 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza